Kronos Bio and Invivoscribe Partner on Companion Diagnostic fo...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SAN MATEO, Calif. and SAN DIEGO, Aug. 17, 2022 /PRNewswire-AsiaNet/ -- - Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML- Entospletinib is currently being studied in the Phase 3 AGIL...
Authors: LATEST ASIANET NEWS RELEASES